Prueba broncodilatadora en pacientes con EPOC estable

Archivos de Bronconeumologia

Volumn 36, Issue 6, 2000, Pages 334-343

  Heredia Budo J L ^a   Rodriguez Carballeira M ^a  

^a HOSPITAL MÚTUA DE TERRASSA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT;

REVIEW;

EID: 0033924910     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2896(15)30153-8     Document Type: Article

References (130)

1. Brown RH, Zerhouni EA, Mitzner W. Variability in the size of individual airways over the course of one year. Am J Respir Crit Care Med 1995; 51: 1159-1164.
2. Hruby J, Butler J. Variabiliy of routine pulmonary function tests. Thorax 1975; 30: 548-553.
3. Dawson A. Reproducibility of spirometric measurements in normal subjects. Am Rev Respir Dis 1966; 93: 264-268.
4. Herold CJ, Brown RH, Mitzner W, Links JM, Hirsman CA, Zerhouni EA. High resolution computed tomography: a new method to asses pulmonary airway reactivity. Radiology 1991; 181: 374-396.
5. Brown RH, Herold CJ, Hirsman CA, Zerhouni Ea, Mitzner W. In vivo measurement of airway rectivity using high-resolution computed tomography. Am Rev Respir Dis 1991; 144: 208-212.
6. Wood SA, Zerhouni EA, Hoford JD, Hoffman EA, Mitzner W. Measurement of three-dimensional lung tree y using computed tomography. J Appl Physiol 1995; 79: 1687-1697.
7. Rozas CJ, Goldman AL. Daily spirometric variability: normal subjets and subjets with chronic bronchitis with and without airflow obstruction. Arch Intern Med 1982; 142: 1287-1291.
8. Nickereson BG, Lemen RJ, Gerdes CB, Wegmann MJ, Rodertson G. Within-subject variability and percent change for significance of spirometry in normal subjects and in patients with cystic fibrosis. Am Rev Respir Dis 1980; 122: 859-866.
9. Nagai A, Yamawaki I, Takizawa T, Thurlbeck WM. Alveolar attachments in emphysema of human lungs. Am Rev Respir Dis 1991; 144: 888-891.
10. Wright J, Cagle L, Churg A, Colby TV, Myers J. Diseases of the small airways. Am Rev Respir Dis 1992; 146: 240-262.
11. Anthonisen NR, Wright EC, y el IPPB Trial Group. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133: 814-819.
12. Committee on emphysema American College of Chest Physicians. Criteria for the assessment of reversibility in airways obstruction. Chest 1974; 65: 552-553.
13. Snider GL, Woolf CR, Kory RC, Ross J. Criteria for the assessment of reversibility in air-ways obstruction. Report of the Committee on Emphysema: American College of Chest Physicians. Chest 1974; 65: 552-553.
14. Ries A. Response to bronchodilators. En: Clausen JL, editor. Pulmonary function testing guidelines and controversies. Orlando. Game? Stration 1984; 215-221.
15. SEPAR. Normativa para la práctica de la espirometría forzada. Arch Bronconeumol 1989; 25: 132-142.
16. a ed.). Londres: Blackwell Scientific, 1979.
17. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991; 144: 1202-1218.
18. Quanjer PhH, Tammeling GS, Cotes JE, Pedersen OF, Peslin R, Yennault JC. Lung volumes and forced ventilatory flows. Resport working party standardization of lung function tests. European Community for steel and coal. Eur Respir J 1993; 6 (Supl 16): 5-40.
19. ATS Statement. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152 (Supl): 77-120.
20. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P et al, on behalf of the Task Force. ERS Consensus Statement. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8: 1398-1420.
21. Díez Herranz A, Tobal González M. La interpretación de la espirometría: ¿dónde nos encontramos? Arch Bronconeumol 1996; 32: 475-482.
22. Harf A. How to express the reversibility of bronchial obstruction? Eur Respir J 1992; 5: 919-920.
23. Selroos O, Pietinalho, Riska H. Delivery devices for inhaled asthma medication - Clinical implications of differences in effectiveness. Clin Immunotherapy 1986; 54: 287-288.
24. Short Md, Singh CA, Few JD, Studdy PR, Heaf PJD, Spiro SG. The labelling and monitoring of lung deposition of an inhaled synthetic anticholinergic bronchodilating agent. Chest 1981; 80 (Supl): 918-921.
25. Newman SP, Weisz AWB, Talaee N, Clark. Improvement of drug delivery with a breath actuated pressurized aerosol for patients with poor inhaler technique. Thorax 1991; 46: 712-716.
26. Zamuidin BN, Biddiscombe M, Tolfree SEJ, Short M, Spiro SG. Comparison of bronchodilatador response and deposition patterns of salbutamol inhaladed from a pressurised aerosol metered dose inhaler, as a dry powder and as a nebulised solution. Thorax 1993; 45: 469-473.
27. Borgstrom L, Bondesson E, Moren F, Trofast E, Newman SP. Lung deposition of budesonide inhaled via turbuhaler: a comparison with terbutaline in normal subjets. Eur Respir J 1994; 7: 69-73.
28. Newman SP, Nillar AB, Lennard-Jones, Moren F, Clarke SW. Improvement of pressurized aerosol deposition with Nebuhaler spacer device. Thorax 1984; 39: 935-941.
29. Melchor R, Biddiscombe MF, Mak VHF, Shooort MD, Spiro SG. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax 1993; 48: 506-511.
30. Corris PA, Neville E, Nariman S, Gibson GJ. Dose-response study of inhaled salbutamol powder in chronic airflow obstruction. Thorax 1983; 38: 292-296.
31. Britton J, Tatterfield A. Comparison of cumulative and non-cumulative techniques to mesure dose-response curves for beta-agonists in patients with asthma. Thorax 1984; 39: 579-599.
32. Shim C. Response to bronchodilatos. Clin Chest Med 1989; 10: 155-164.
33. Potsma DS, Vries KD, Koeter GH, Sluiter HJ. Independent influence of reversibility of airflow obstruction and nonspecific hyperreactivity on the long-term course of lung function in chronic airflow obstruction. Am Rev Respir Dis 1986; 134: 276-280.
34. Tashkin DP, Ashutosh K, Bleecker ER, Birtt EJ, Cugell DW, Cummiskey JM et al. Comparison of the anticholinergic bronchodilator ipratropium bromide with metaporterrenol in chronic obstructive pulmonary disease. A 90 day multi-centre study. Am J Med 1986; 81 (Supl 5A): 81-90.
35. Mayos M, González M, Casán P, García-Barbal J, Sanchís J. Comparación entre procaterol y salbutamol mediante dosis-respuesta acumulada en pacientes con limitación crónica al flujo aéreo. Arch Bronconeumol 1989; 25: 65-68.
36. Nisar M, Walshaw M, Earis JE, Pearson MG, Calverly PM. Assessment of reversibility of airway obstruction in patients with chronic obstructive airways disease. Thorax 1990; 45: 190-194
37. Kerstjens HAM, Brand PLP, Quanjer PH, Van deer Bruggen-Bogaarts BAHA, Koëter GH, Postma DS, on behalf of the Dutch CNSLD Study Group. Variability of bronchodilator response and effects of inhalad corticosteroid treatment in obstructive airways disease. Thorax 1993; 48: 722-729.
38. Nisar M, Earis JE, Pearson MG, Calverly PMA. Acute bronchodilator trials in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 146: 555-559.
39. Braun SR, Mckenzie WN, Copeland C, Knight L, Ellersieck M. A comparison of the effect of ipratropium and albuterol in the treatment of chronic obstructive airway disease. Arch Intern Med 1989; 149: 544-547.
40. Newnham DM, Dhillon DP, Winter JH, Jackson CM, Clark RA, Lipworth BJ. Brochodilator reversibility to low and high doses of terbutaline and ipratropium bromide in patients with chronic obstructive pulmonary disease. Thorax 1993; 48: 1151-1155.
41. Jenkins SC, Moxham J. High dose salbutmol in chronic bronchitis: comparison of 400 mg, 1 mg, 1.6 mg, 2 mg and placebo delivered by rotahalar. Br J Dis Chest 1987; 81: 242-247.
42. Lipworth BJ, Clark RA, Dhillon DP, McDevitt DG. Comparison of the effects of prolonged treatment with low and high doses of inhaled terbutaline on beta-adrenoeptor responsiveness in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1990, 142: 338-342.
43. Gómez L, Rodríguez-Carballeira M, Quintana S, Esteban L, Viñas C, Heredia JL. The bronchodilator response with increasing dose of terbutalina. Eur Respir J 1994; 7: S330.
44. Rodríguez-Carballeira M. Prueba broncodilatadora en pacientes con enfermedad pulmonar obstructiva crónica [Tesis doctoral]. Barcelona: Universidad Autónoma de Barcelona, 1999.
45. Jaesckie R, Guyatt GH, Cook D, Morris J, Willan A, McIlroy W et al. The effect of increasing doses of β-agonist on airflow in patients with chronic airflow limitation. Respir Med 1993; 87: 433-438
46. Klock LE, Miller TD, Morris AH, Watanabe S, Dickman M. A comparative study of atropine sulfate and isoproterol hydrochloride in chronic bronchitis. Am Rev Respir Dis 1975; 112: 371-376.
47. Ashutosh K, Dev G, Steele D. Non bronchodilator effects of pirbuterol and ipratropium in chronic obstructive pulmonary disease. Chest 1995; 107: 173-178.
48. Ikeda A, Nishimura K, Koyama H, Izumi T. Comparative dose-response study of three antichollinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease. Thorax 1993; 50: 62-66.
49. Wesseling G, Mostert R, Wouters EFM. A comparison of the effects of anticholinergic and beta-2-agonist and combination therapy on respiratory impedance in COPD. Chest 1992; 101: 166-173.
50. Lloberas P, Ramis L, Montserrat JM, Serra J, Campistol J, Picado C, Agustí-Vidal A. Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease. Eur Respir J 1988; 1: 536-539.
51. Braun SR, Levy SF, Grossman J. Comparison of ipratropium bromide and albuterol in chronic obstructive pulmonary disease: a three-center study. Am J Med 1991; 91 (Supl 4A): 28-32.
52. Imhof E, Elsasser S, Karrer W, Grossenbacher M, Emmons R, Perruchoud AP. Comparison of bronchodilator effect of fenoterol/ipratropium bromide and salbutamol in patients with chronic obstructive lung disease. Respiration 1993; 60: 84-88.
53. Petrie GR, Palmer KNV. Comparison of aerosol ipratropium bromide and salbutamol in chronic bronchitis and asthma. Br Med J 1975; 1: 430-432.
54. Douglas NJ, Davidson I, Sudlow MF, Flenley DC. Bronchodilation and the site of airway resistance in severe chronic bronchitis. Thorax 1979; 34: 51-56.
55. Hughes JA, Tobin MJ, Bellamy D, Hutchison DCS. Effects of ipratropium bromide and fenoterol aerosols in pulmonary emphysema. Thorax 1982; 37: 667-670.
56. Rodríguez-Carballeira M, Heredia JL, Gómez L, Quintana S, Viñas C. Contribution of Ipratropium Bromide of the bronchodilator test in patients with chronic obstructive pulmonary disease. Pulmon Pharmacol Ther 1999; 12: 43-48.
57. Rodríguez-Carballeira M, Rué M, Quintana S, Gómez L, Heredia JL. Bronchodilator test with terbutaline and ipratropium bromide in patients with COPD. Eur Respir J 1997; 10 (Supol 25): 37.
58. Marini JJ, Lakshminarayan S. The effect of atropine inhalation in "irreversible" chronic bronchitis. Chest 1980; 77: 591-596.
59. Passamonte PM, Martínez AJ. Effect of inhaled atropine or metaproterenol in patients with chronic airway obstruction and therapeutic serum theophylline levels. Chest 1984; 85: 610-615.
60. Quadrelli SA, Roncoroni AJ, Porcel G. Analysis of variability in interpretation of spirometric tests. Respiration 1996; 63: 131-136.
61. Light RW, Conrad SA, George RB. Clinical significance of pulmonary function tests. The one best test for evaluating the effects of bronchodilator therapy. Chest 1977; 72: 512-516.
62. Pennock BE, Rogers RM, McCaffree DR. Changes in measured spirometric indices. What is significant? Chest 1981; 80: 97-99.
63. Berger R, Smith D. Acute postbronchodilator changes in pulmonary function parameters in patients with chronic airways obstruction. Chest 1988; 93: 541-546.
64. Barrons MJ, Rees PJ. Bronchodilator responses to salbutamol followed by ipratropium bromide in partially reversible airflow obstruction. Respir Med 1990; 84: 311-315.
65. Noah MS, Kabiraj MM, Abdullah AK, Zaman AU. Measurement of reversibility of airways obstruction: which parameters to use? Respiration 1985; 48: 24-28.
66. 1 and bronchodilator responsiveness in patients with obstructive ventilatory defects. Thorax 1987; 42: 487-490.
67. Ramsdell JW, Tisi GM. Determination of bronchodilation in the clinical pulmonary function laboratory. Chest 1979; 76: 622-628.
68. 1 and peak expiratory flow in patients with chronic airflow obstruction. Thorax 1988; 43: 335-336.
69. Dekker FW, Schrier AC, Sterk PJ, Dijkman JH. Validity of peak expiratory flow measurement in assessing of airway obstruction. Thorax 1992; 47: 162-166.
70. a ed.). Oxford: Blackwell Scientific Publications, 1994.
71. Ayres SM, Griesbach SJ, Reilmond F, Evans RG. Bronchial component in chronic obstructive lung disease. Am J Med 1974; 57: 183-191.
72. Baker TR, Oscherwitz M, Corlin R, Jaiboe E, Teisch J, Nichaman MZ. Screening and treatment program for mild chronic obstructive pulmonary disease. JAMA 1970; 214: 1448-1455.
73. Prieto L, Lamarca R, Casado A. La evaluación de la fiabilidad en las observaciones clínicas: el coeficiente de correlación intraclase. Med Clin (Barc) 1998; 110: 142-145.
74. Mora Ripoll R, Ascaso Terrén C, Sentís Vialta J. Uso actual de la estadística en investigación biomédica: una comparación entre revistas de medicina general. Med Clin (Barc) 1996; 106: 451-456.
75. Mora Ripoll R, Ascaso Terrén C, Sentís Vialta J. Tendencias actuates en la utilización de la estadística en medicina. Estudio de los artículos publicados en Medicina Clínica (1991-1992). Med Clin (Barc) 1995; 104: 444-447.
76. Guyatt GH, Townsend M, Nogradi S, Pugsley S, Keller J, Newhouse MT. Acute response to bronchodilator. Arch Intern Med 1988; 148: 1949-1952.
77. Gabriel Sánchez R, Villasante Fernández-Montes C, Pino García JM, García Río F, Miravitlles M, Jiménez Ruiz CA et al. Estimación de la variabilidad initial interobservador de la espirometría forzada en el estudio epidemiológico multicéntrico IBERCOP. Arch Bronconeumol 1997; 33: 300-305.
78. Chinn S, Britton JR, Burney PGJ, Tattersfield AE, Papacosta AO. Estimation and repeatibility of the response to inhaled histamine in a community survey. Thorax 1987; 42: 45-52.
79. Meslier N, Racinaux JL. Test of reversibility of airway obstruction. Eur Respir Rev 1991; 1: 34-40.
80. Brand PL, Quanjer PH, Postma DS, Kerstjens HAM, Koëter GH, Dekhuijzen PNR, Sluiter HJ, y el Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group. Interpretation of bronchodilator response in patients with obstructive airways disease. Thorax 1992; 47: 429-436.
81. Meslier N, Racineux JL, Six P, Lockhart A. Diagnostic value of reversibility of chronic airway obstruction to separate asthma from chronic bronchitis: a statistical approach. Eur Respir J 1989; 2: 497-505.
82. Weir DC, Burge PS. Measures of reversibility in response to bronchodilators in chronic airflow obstruction: relation to airway calibre. Thorax 1991; 46: 43-45.
83. Gayrard P, Orehek J. Mesure d'un effet bronchodilateur par le VEMS: comment l'exprimer? Rev Mail Respir 1984; 1: 81-84.
84. Demedts M. The assessment of reversibility: what physiological tests? Eur Respir J 1990; 3: 1084-1087.
85. 1. Eur Respir J 1992; 5: 975-981.
86. Postma DS, Gimeno F, Weele LTHVD, Sluiter HJ. Assessment of ventilatory variables in survival prediction of patients with chronic airflow obstruction: the importance of reversibility. Eur J Respir Dis 1985; 67: 360-368.
87. Miller MR, Pincock AC. Predicted values: how should we use them? Thorax 1988; 43: 265-267.
88. Chinn S. Repeatability and method comparison. Thorax 1991; 46: 454-456.
89. Dales RE, Spitzer WO, Tousignant P, Schechter M. Clinical interpretation of airway response to a bronchodilator. Epidemiologic considerations. Am Rev Respir Dis 1988; 138: 317-320.
90. Anthonisen NR, Wright EC, e IPPB Trial Groups. Response to inhaled bronchodilators in COPD. Chest 1987; 91 5 (Supl): 36-39.
91. Pratter MW, Irwin RS. Predicting response to bronchodilator therapy in chronic obstructive pulmonary disease. Arch Intern Med 1988; 148: 1909-1910.
92. Gómez L, Rodríguez-Carballeira M. Quintana S, Esteban L, Viñas C, Heredia JL. Espirometrías repetidas en pacientes con enfermedad pulmonar obstructiva crónica: variabilidad de la prueba broncodilatadora. Arch Bronconeumol 1994; 30 (Supl 1): 152-153.
93. Eliasson O, Degraff AC. The use of criteria for reversibility and obstruction to define patients groups for bronchodilator trials. Am Rev Respir Dis 1985; 132: 858-864.
94. Ferguson GT, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med 1993; 328: 1017-1022.
95. Guyatt GH, Townsend M, Nogradi S, Pugsley SO, Keller JL, Newhouse MT. Acute response to bronchodilator. Arch Intern Med 1988; 148: 1949-1952.
96. Rodŕguez-Carballeira M, Gómez L, Quintana S, Rue M, Esteban L, Viñas C et al. Estudio de broncorreversibilidad en pacientes con EPOC severa. Arch Bronconeumol 1996; 32 (Supl 2): 8.
97. Dull WL, Alexander MR, Sadoul P, Woolson RF. The efficacy of isoproterenol inhalation for predicting the response to orally administered theophylline in chronic obstructive pulmonary disease. Am Rev Respir Dis 1982; 126: 656-659.
98. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751-758.
99. Mahler DA, Rosiello RA, Harver A, Lentine T, McGovern JF, Daubenspeck JA. Comparison of clinical dyspnea ratings and psychophysical measurements of respiratory sensation in obstructive airway disease. Am Rev Respir Dis 1987; 135: 1229-1233.
100. Mahler DA, Matthay RA, Snyder PE, Wells CK, Loke J. Sutained-release theophylline reduces dyspnea in nonreversible obstructive airway disease. Am Rev Respir Dis 1985; 131: 22-25.
101. Eaton ML, MacDonald FM, Church TR, Niewoehner DE. Effects of theophylline on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Chest 1982; 82: 538-542.
102. Heredia JL, Rodríguez M, Quintana S, Mir I, Viñas C, Gómez L. Percepción de mejoría en el asma. Med Clin (Barc) 1995; 105: 612-614.
103. Jones PW. Issues concerning health-related quality of life in COPD. Chest 1995; 107 (Supl 5): 187-193.
104. Noseda A, Schmerber J, Prigogine T, Yemault JC. How do patients with either asthma or COPD perceive acute bronchodilation? Eur Respir J 1993; 6: 636-644.
105. Lorber DB, Kaltenborn W, Burrows B. Responses to isoproterenol in a general pupulation sample. Am Rev Respir Dis 1978; 118: 855-861.
106. Boushey HA, Holtzman MJ, Sheller JR, Nadel JA. Bronchial Hyperreactivity. Am Rev Respir Dis 1980; 121: 389-413.
107. Burrows B, Earle RH. Course and prognosis of chronic obstructive lung disease. A prospective study of 200 patients. N Engl J Med 1969; 280: 397-404.
108. Traver GA, Cline MG, Burrows B. Predictors of mortality in chronic obstructive pulmonary disease. Am Rev Respir Dis 1979; 119: 895-902.
109. Postma DS, Sluitter HJ. Predictors of mortality in chronic obstructive pulmonary disease. Am Rev Respir Dis 1980; 121: 1056-1057.
110. Postma DS, Burema J, Gimeno F, May JF, Smit JM, Steenhuis EJ et al. Prognosis in severe chronic obstructive pulmonary disease. Am Rev Respir Dis 1979; 119: 357-367.
111. 1 in chronic bronchitis. Aust NZ J Med 1974; 4: 339-345.
112. Barter CE, Campbell AH, Relationship of constitutional factors and cigarette smoling to decrease in 1-second forced expiratory volume. Am Rev Respir Dis 1976; 113: 305-314.
113. Vollmer WM, Johnson LR, Buist AS. Relationship of response to a bronchodilator and decline in forced expiratory volume in one second in population studies. Am Rev Respir Dis 1985; 132: 1186-1193.
114. Pellicer Ciscar C, Perpiñá Tordera M, De Diego Damiá A, Macián Gisbert V. Aportación del test broncodilatador al estudio de la reversibilidad bronquial. Arch Bronconeumol 1994; 30: 492-497.
115. Kesten S, Rebuck AS. Is the shot-term response to inhaled β adrenergic agonist sensitive or specific for distinguishing between asthma and COPD? Chest 1994; 105: 1042-1045.
116. Minette A. Spirometric study of the bronchodilation effects of hydroxyphenylorciprenaline (Th 1165 a) in various forms in a group of 124 coal miners suffering from bronchospasm. Respiration 1970; 27: 276-315.
117. Vathenen AS, Britton JR, Ebben P, Cookson JB, Wharrad HJ. Tattersfield AE. High-dose inhaled albuterol in severe chronic airflow limitation. Am Rev Respir Dis 1988; 138: 850-855.
118. Barnes PJ, Pedersen S, Busse WW. Supplement: efficacy and safety of inhaled corticosteroids: news developments. Am J Respir Crit Care Med 1998; 157: S1-S59.
119. Burge PS. EUROSCOP, ISOLDE and the Copenhagen City Lung Study. Thorax 1999; 54: 287-288.
120. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth F, Efhimiou J, on behalf of the International COPD Study Group. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998; 351: 773-780.
121. Van Grusven PM, Van Schayck CP, Derenne JP, Kerstjens HA, Renkema TEJ, Postma DS et al. Long term effects of inhaled corticostcroids in chronic obstructive pulmonary disease: a metaanalysis. Thorax 1999; 54: 7-14.
122. Pawles RA, Löfdahl CG, Laininen LA, Schouten JP, Postma DS, Pride NB et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive disease who continue smoking. N Engl J Med 1999; 340: 1948-1953.
123. Harding SM, Freedman SA. A comparison of oral and inhaled steroids in patients with chronic airways obstruction: features determining response. Thorax 1978; 33: 214-218.
124. Mendella LA, Manfreda J, Warren CPW, Anthonisen NR. Steroids response in stable chronic obstructive pulmonary disease. Ann Intern Med 1982; 96: 17-21.
125. Weiner P, Weiner M, Azgad Y, Damir D. Inhaled budesonide therapy for patients with stable COPD. Chest 1995; 109: 1568-1571.
126. Van Schayck CP, Van Grusven PM, Dekhuijzen PNR. Do patients with COPD benefit from treatment with inhaled corticosteroidea? Eur Respir J 1996; 9: 1969-1972.
127. 1 during long-term inhaled corticosteroid treatment. Eur Respir J 1993; 6: 868-876.
128. Dompeling E, Van Schayck CP, Van Grunsven PM, Van Herwaarden CLA, Akkermans R, Molema J et al. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhlaed corticosteroids. A 4-year prospective study. Ann Intern Med 1993; 118: 770-778.
129. Kerstjens HA, Brand PL, Hughes MD, Robinson NJ, Postma DS, Sluiter HJ et al, and the Dutch Chronic Non-Specific Lung Disease Study Group. A comparison of bronchodilator therapy for obstructive airways disease. N Engl J Med 1992; 327: 1413-1419.
130. Rutten-Van Mölken MP, Van Doorslaer EK, Jansen MC, Kerstjens HA, Rutten FF. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 151: 975-982.